 Artist: Joey Ramone: mp3 download Genre(s): Rock: Punk-Rock Joey Ramone's discography:  Don't Worry About Me Year: 2002 Tracks: 11  Christmas Spirit Year: 2002 Tracks: 5  With 22Jacks Viper Room Year: 1997 Tracks: 10 Joey Ramone's signature bleat was the articulation of touchwood sway in America. Sporting a leather jacket and lacerate jeans (like his bandmates) and concealment his cheek behind a geminate of dark specs and a deep shock of dark haircloth, the rangy Ramone helped delineate punk's early persona as well and his two-decade-plus term of office as frontman of the Ramones made him a countercultural image. Ramone was born Jeffrey Hyman on May 19, 1951 (though he often claimed the year was 1952) in Forest Hills, voice of the Queens section of New York City. Rock & roll gave the teen Joey Ramone an evasion from his parents' split up and he began playing in glam-influenced bands in the early '70s. He co-founded the Ramones in 1974 with friends John Cummings and Douglas Colvin, upon which point all threesome adoptive Ramone as their stage family name. Joey Ramone ab initio served as the group's drummer earlier switch to vocals and having his former bit taken by handler Tommy Erdelyi. The Ramones promptly became regulars at the Bowery club CBGB's and their brief, rapid-fire concert expressive style became the stuff and nonsense of legend. When the Ramones recorded their debut album in 1976, it heralded the true birth of punk stone; although groups care the Stooges, MC5, and New York Dolls laid the groundwork, the Ramones' truancy, three-chord songwriting, cheerfully dense temper, and unbounded vigour created the blueprint that innumerable hoodlum bands would watch over in the decades to come. Their 1976 duty tour of the U.K. helped heat that country's punk setting as well and their impact on American music was never more plain than in the '90s, when a host of punk-pop bands world Health Organization never could have existed without the Ramones' music took that legal to the top of the charts. Contempt their enormous influence, a life history that spanned iI decades, and a smattering of undisputedly authoritative albums, the Ramones never became stars in their own good -- even though the sound they'd pioneered came to overshadow democratic music during to the highest degree of the '90s and even though the striation recorded during that x with a fresh clean and serious focus. After touring with the 1996 Lollapalooza festival, the Ramones all over that the stardom they'd always coveted was never to be and they disbanded ahead the end of the year. Despite having released the collaborative EP In a Family Way with his brother Mickey Leigh in 1994 (under the cite Sibling Rivalry), Joey Ramone largely shunned the spot following the dissolution. He did make occasional populace appearances and worked for a clock time as a radiocommunication DJ; toward the goal of the decade, he besides began working sporadically on a solo disk. He assembled a ring featuring guitar player Daniel Rey, bassist Andy Shernoff (ex-Dictators), and drummer Frank Funaro (Cracker) and played several gigs in the New York expanse. Sadly, in front the record could be completed, Ramone succumbed to lymphatic genus Cancer on April 15, 2001; he was 49 days old. |
Tuesday 2 September 2008
Mp3 music: Joey Ramone
Saturday 23 August 2008
Bayer And Onyx Begin Enrollment In STORM Trial Studying Nexavar As Adjuvant Therapy For Patients With Liver Cancer
�Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc.
(Nasdaq: ONXX) announced the companies take in begun enrolling patients
in the STORM Sorafenib as Adjuvant Treatment in the Prevention of
Recurrence of Hepatocellular Carcinoma trial. The randomized, double blind,
placebo-controlled Phase 3 study is evaluating Nexavar(R) (sorafenib)
tablets as adjuvant handling, which is treatment following surgery or
local radiation, for patients with hepatocellular carcinoma (HCC), or
primary liver cancer.
"Nexavar is the only systemic therapy with proven efficacy and
tolerability in HCC across multiple patient populations," aforesaid Dimitris
Voliotis, MD, vice president, Nexavar Clinical Development, Bayer
HealthCare Pharmaceuticals. "Liver cancer is the third largest world
cancer killer worldwide and there is a important need for new therapies
that can buoy be used at all stages in the course of action of the disease to delay
disease progression and prolong life."
In addition, the U.S. Food and Drug Administration (FDA) has completed
a Special Protocol Assessment (SPA) for the STORM test. An SPA is a
written arrangement on the design and size of a clinical trial intended to
form the basis for a new drug application.
Phase 3 Trial Design
The international multicenter study is expected to inscribe approximately
1,100 patients and volition include patients who have received surgical
resection or local excision. The survey will see at whether providing oral
Nexavar in the adjuvant setting delays the prison term to return and increases
overall survival. The primary endpoint of the study is return free
endurance. Secondary endpoints include boilersuit survival, time to recurrence,
patient-reported outcomes, plasma biomarkers, safety and tolerability.
The study is enrolling patients with all HCC histologies. Patients will
be randomized to incur 400 mg of Nexavar twice casual or coordinated placebo
for up to four geezerhood. The discipline will be conducted at more than 200 sites in
North America, South America, Europe and the Asia-Pacific region, including
Japan. For information about enrolling in the study, please visit
hypertext transfer protocol://www.clinicaltrials.gov.
Hepatocellular carcinoma is the most common shape of liver cancer and is
responsible for about 90 pct of the primary malignant liver tumors in
adults. Liver cancer is the sixth most common cancer in the world and the
third base leading cause of cancer-related deaths globally. More than 600,000
cases of liver cancer are diagnosed worldwide each year (more than cd,000
in China, South Korea, Japan and Taiwan, 54,000 in the European Union, and
15,000 in the United States) and the relative incidence is increasing. In 2002,
approximately 600,000 people died of liver cancer the Crab including some
370,000 in China, South Korea and Japan, 57,000 in the European Union, and
13,000 in the United States.(1,2)
Currently there are no adjuvant treatments with proven benefit in HCC
and half of the patients wHO have undergone surgical resection or local
ablation will see their tumors render within 3 years and 70 percent
will witness their tumors return within five years.(3)
Nexavar's Differentiated Mechanism
Nexavar targets both the tumor electric cell and tumor vasculature. In
preclinical studies, Nexavar has been shown to objective members of two
classes of kinases known to be involved in both cell proliferation (growth)
and angiogenesis (origin supply) -- two important processes that enable
crab growth. These kinases included Raf kinase, VEGFR-1, VEGFR-2,
VEGFR-3, PDGFR-B, KIT, FLT-3 and RET.
Nexavar is currently sanctioned in more than 40 countries for liver
genus Cancer and in more than 70 countries for the treatment of patients with
advanced kidney cancer. Nexavar is likewise being evaluated by the companies,
outside study groups, government agencies and single
investigators as a single agent or combination treatment in a wide range of
cancers, including metastatic melanoma, lung cancer, white meat cancer and as
an adjuvant therapy for kidney cancer.
Important Safety Considerations For Patients Taking Nexavar
Based on the currently sanctioned U.S. software insert for the treatment
of patients with unresectable hepatocellular carcinoma, hypertension english hawthorn
occur early in the course of therapy and blood pressure should be monitored
weekly during the first six-spot weeks of therapy and treated as needed.
Bleeding with a fatal consequence from any site was reported in 2.4% for
Nexavar and 4% in placebo. The incidence of treatment-emergent cardiac
ischemia/infarction was 2.7% for Nexavar vs. 1.3% for placebo. Most plebeian
adverse events reported with Nexavar in patients with unresectable HCC were
looseness of the bowels, fatigue, ab pain, weight loss, anorexia, nausea and
hand-foot skin reaction. Grade 3/4 inauspicious events were 45% for Nexavar vs.
32% for placebo. Women of accouchement potential should be advised to
quash becoming meaning and advised against nursing. In cases of whatever
severe or persistent position effects, temporary treatment disruption, dose
qualifying or lasting discontinuation should be considered.
About Bayer HealthCare Pharmaceuticals Inc.
Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals
unit of Bayer HealthCare LLC, a division of Bayer AG. One of the world's
leading, modern companies in the healthcare and medical products
manufacture, Bayer HealthCare combines the global activities of the Animal
Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the
U.S., Bayer HealthCare Pharmaceuticals comprises the following business
units: Women's Healthcare, Diagnostic Imaging, Specialized Therapeutics,
Hematology/Cardiology and Oncology. The company's get is to discover and
manufacture products that will improve human health global by
diagnosis, preventing and treating diseases.
About Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to
improving the lives of people with cancer. The company, in collaboration
with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing
Nexavar(R) (sorafenib) tablets, a small particle drug. For more info
about Onyx, visit the company's internet site at http://www.onyx-pharm.com.
Forward Looking Statements
This news release may contain forward-looking statements based on
current assumptions and forecasts made by Bayer Group or subgroup
management. Various known and unknown risks, uncertainties and other
factors could lead to material differences between the actual future
results, financial situation, development or performance of the company and
the estimates given here. These factors include those discussed in Bayer's
populace reports which are uncommitted on the Bayer Web site at
http://www.bayer.com. The party assumes no liability whatsoever to update
these modern statements or to conform them to future events or
developments.
This news show release as well contains "innovative statements" of Onyx
inside the substance of the federal securities laws. These forward-looking
statements include without limitation, statements regarding the results of
the clinical development, refuge, regulatory processes, commercialization
efforts or commercial potential of Nexavar. These statements are subject to
risks and uncertainties that could cause actual results and events to
differ materially from those anticipated. Reference should be made to
Onyx's Annual Report on Form 10-K for the year ended % 31, 2007,
filed with the Securities and Exchange Commission under the heading "Risk
Factors" and Onyx's Quarterly Reports on Form 10-Q for a more elaborated
description of such factors. Readers ar cautioned not to place undue
trust on these forward-looking statements that talk only as of the date
of this release. Onyx undertakes no responsibility to update publicly whatever
forward-looking statements to reverberate new data, events, or
circumstances after the date of this release except as required by law.
Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer
HealthCare Pharmaceuticals, Inc.
References
(1) Ferlay J, et al., GLOBOCAN 2002. Cancer Incidence, Mortality and
Prevalence Worldwide. IARC CancerBase No.5, Version 2.0. IARCPress,
Lyon, 2004. Available at: hTTP://www-dep.iarc.fr. Accessed May 2008.
(2) 2005 Cancer Register System (CRS) annual report,
http://crs.cph.ntu.edu.tw/crs_c/annual.html. Accessed May 12, 2008.
(3) Del Pozo AC, Lopez P. Management of hepatocellular carcinoma. Clin
Liver Dis 2007 May;11(2):305-21.
Onyx Pharmaceuticals, Inc
http://www.onyx-pharm.com
View dose information on Nexavar.
More information
(Nasdaq: ONXX) announced the companies take in begun enrolling patients
in the STORM Sorafenib as Adjuvant Treatment in the Prevention of
Recurrence of Hepatocellular Carcinoma trial. The randomized, double blind,
placebo-controlled Phase 3 study is evaluating Nexavar(R) (sorafenib)
tablets as adjuvant handling, which is treatment following surgery or
local radiation, for patients with hepatocellular carcinoma (HCC), or
primary liver cancer.
"Nexavar is the only systemic therapy with proven efficacy and
tolerability in HCC across multiple patient populations," aforesaid Dimitris
Voliotis, MD, vice president, Nexavar Clinical Development, Bayer
HealthCare Pharmaceuticals. "Liver cancer is the third largest world
cancer killer worldwide and there is a important need for new therapies
that can buoy be used at all stages in the course of action of the disease to delay
disease progression and prolong life."
In addition, the U.S. Food and Drug Administration (FDA) has completed
a Special Protocol Assessment (SPA) for the STORM test. An SPA is a
written arrangement on the design and size of a clinical trial intended to
form the basis for a new drug application.
Phase 3 Trial Design
The international multicenter study is expected to inscribe approximately
1,100 patients and volition include patients who have received surgical
resection or local excision. The survey will see at whether providing oral
Nexavar in the adjuvant setting delays the prison term to return and increases
overall survival. The primary endpoint of the study is return free
endurance. Secondary endpoints include boilersuit survival, time to recurrence,
patient-reported outcomes, plasma biomarkers, safety and tolerability.
The study is enrolling patients with all HCC histologies. Patients will
be randomized to incur 400 mg of Nexavar twice casual or coordinated placebo
for up to four geezerhood. The discipline will be conducted at more than 200 sites in
North America, South America, Europe and the Asia-Pacific region, including
Japan. For information about enrolling in the study, please visit
hypertext transfer protocol://www.clinicaltrials.gov.
Hepatocellular carcinoma is the most common shape of liver cancer and is
responsible for about 90 pct of the primary malignant liver tumors in
adults. Liver cancer is the sixth most common cancer in the world and the
third base leading cause of cancer-related deaths globally. More than 600,000
cases of liver cancer are diagnosed worldwide each year (more than cd,000
in China, South Korea, Japan and Taiwan, 54,000 in the European Union, and
15,000 in the United States) and the relative incidence is increasing. In 2002,
approximately 600,000 people died of liver cancer the Crab including some
370,000 in China, South Korea and Japan, 57,000 in the European Union, and
13,000 in the United States.(1,2)
Currently there are no adjuvant treatments with proven benefit in HCC
and half of the patients wHO have undergone surgical resection or local
ablation will see their tumors render within 3 years and 70 percent
will witness their tumors return within five years.(3)
Nexavar's Differentiated Mechanism
Nexavar targets both the tumor electric cell and tumor vasculature. In
preclinical studies, Nexavar has been shown to objective members of two
classes of kinases known to be involved in both cell proliferation (growth)
and angiogenesis (origin supply) -- two important processes that enable
crab growth. These kinases included Raf kinase, VEGFR-1, VEGFR-2,
VEGFR-3, PDGFR-B, KIT, FLT-3 and RET.
Nexavar is currently sanctioned in more than 40 countries for liver
genus Cancer and in more than 70 countries for the treatment of patients with
advanced kidney cancer. Nexavar is likewise being evaluated by the companies,
outside study groups, government agencies and single
investigators as a single agent or combination treatment in a wide range of
cancers, including metastatic melanoma, lung cancer, white meat cancer and as
an adjuvant therapy for kidney cancer.
Important Safety Considerations For Patients Taking Nexavar
Based on the currently sanctioned U.S. software insert for the treatment
of patients with unresectable hepatocellular carcinoma, hypertension english hawthorn
occur early in the course of therapy and blood pressure should be monitored
weekly during the first six-spot weeks of therapy and treated as needed.
Bleeding with a fatal consequence from any site was reported in 2.4% for
Nexavar and 4% in placebo. The incidence of treatment-emergent cardiac
ischemia/infarction was 2.7% for Nexavar vs. 1.3% for placebo. Most plebeian
adverse events reported with Nexavar in patients with unresectable HCC were
looseness of the bowels, fatigue, ab pain, weight loss, anorexia, nausea and
hand-foot skin reaction. Grade 3/4 inauspicious events were 45% for Nexavar vs.
32% for placebo. Women of accouchement potential should be advised to
quash becoming meaning and advised against nursing. In cases of whatever
severe or persistent position effects, temporary treatment disruption, dose
qualifying or lasting discontinuation should be considered.
About Bayer HealthCare Pharmaceuticals Inc.
Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals
unit of Bayer HealthCare LLC, a division of Bayer AG. One of the world's
leading, modern companies in the healthcare and medical products
manufacture, Bayer HealthCare combines the global activities of the Animal
Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the
U.S., Bayer HealthCare Pharmaceuticals comprises the following business
units: Women's Healthcare, Diagnostic Imaging, Specialized Therapeutics,
Hematology/Cardiology and Oncology. The company's get is to discover and
manufacture products that will improve human health global by
diagnosis, preventing and treating diseases.
About Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to
improving the lives of people with cancer. The company, in collaboration
with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing
Nexavar(R) (sorafenib) tablets, a small particle drug. For more info
about Onyx, visit the company's internet site at http://www.onyx-pharm.com.
Forward Looking Statements
This news release may contain forward-looking statements based on
current assumptions and forecasts made by Bayer Group or subgroup
management. Various known and unknown risks, uncertainties and other
factors could lead to material differences between the actual future
results, financial situation, development or performance of the company and
the estimates given here. These factors include those discussed in Bayer's
populace reports which are uncommitted on the Bayer Web site at
http://www.bayer.com. The party assumes no liability whatsoever to update
these modern statements or to conform them to future events or
developments.
This news show release as well contains "innovative statements" of Onyx
inside the substance of the federal securities laws. These forward-looking
statements include without limitation, statements regarding the results of
the clinical development, refuge, regulatory processes, commercialization
efforts or commercial potential of Nexavar. These statements are subject to
risks and uncertainties that could cause actual results and events to
differ materially from those anticipated. Reference should be made to
Onyx's Annual Report on Form 10-K for the year ended % 31, 2007,
filed with the Securities and Exchange Commission under the heading "Risk
Factors" and Onyx's Quarterly Reports on Form 10-Q for a more elaborated
description of such factors. Readers ar cautioned not to place undue
trust on these forward-looking statements that talk only as of the date
of this release. Onyx undertakes no responsibility to update publicly whatever
forward-looking statements to reverberate new data, events, or
circumstances after the date of this release except as required by law.
Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer
HealthCare Pharmaceuticals, Inc.
References
(1) Ferlay J, et al., GLOBOCAN 2002. Cancer Incidence, Mortality and
Prevalence Worldwide. IARC CancerBase No.5, Version 2.0. IARCPress,
Lyon, 2004. Available at: hTTP://www-dep.iarc.fr. Accessed May 2008.
(2) 2005 Cancer Register System (CRS) annual report,
http://crs.cph.ntu.edu.tw/crs_c/annual.html. Accessed May 12, 2008.
(3) Del Pozo AC, Lopez P. Management of hepatocellular carcinoma. Clin
Liver Dis 2007 May;11(2):305-21.
Onyx Pharmaceuticals, Inc
http://www.onyx-pharm.com
View dose information on Nexavar.
More information
Wednesday 13 August 2008
Download Twista
 Artist: Twista: mp3 download Genre(s): Rap: Hip-Hop Other Discography:  Adrenaline Rush 2007 Year: 2007 Tracks: 19  Twista Year: 2004 Tracks: 1  The Day After Year: 2004 Tracks: 15  Kamikaze Year: 2004 Tracks: 16 Chicago rapper Twista made his transcription debut on "Po Pimp," a atomic number 78 single by his dude Windy City rappers Do or Die. Following "Po Pimp," Twista sign-language with Big Beat/Atlantic and released his debut, Adrenalin Rush, in the summer of 1997. Mobstability followed a year later, and in 1999 Twista returned with Legit Ballin'. In settle 2002, Twista hooked up with Ludacris, Jay-Z, Bone Thugs-N-Harmony and other tap moguls for the transcription of his third record album. Kamikaze came out at the beginning of 2004 and readily stumble the Billboard cc, horseback horseback riding the impulsion of his #1 stumble single "Dull Jamz." In 2005 he returned with the record album The Day After and the run into single "Girl Tonite" with Trey Songz. Two eld by and by Adrenaline Rush 2007 appeared. |
Melba Moore
Wednesday 6 August 2008
New York Times Examines Reaction To Tobacco Regulation Legislation
�
The New York Times on Sunday examined how smokers ar left in the middle of "this maelstrom of debate" on whether menthol-flavored cigarettes should be included in the legislation that would allow FDA to ban flavored additives (Navarro, New York Times, 8/3).
The House last week by a veto-proof 326-102 vote approved lawmaking (HR 1108) that would give FDA the confidence to determine tobacco products. The metre, introduced by Rep. Henry Waxman (D-Calif.), would allow FDA to ban flavored additives, with an exemption for menthol flavoring. Some black anti-smoking advocates criticized the exemption, noting that many black smokers use mentholated cigarettes. The National African American Tobacco Prevention Network withdrew its support for the bill because of the menthol exemption. Seventy-five pct of black smokers economic consumption mentholated tobacco products. Menthol brands account for about 28% of the $70 billion U.S. cigarette market.
It is intellection that menthol and other additives mightiness mask the harshness of tobacco, which could cook it easier for teenagers to begin smoking. Researchers also receive questioned whether menthol plays a character in disproportional rates of cancer related to to smoking among blacks. A recent study from Harvard University found that some butt makers by choice "manipulated menthol levels to attract young people" (Kaiser Health Disparities Report, 7/31).
The Times reports that menthol cigarettes have historically been heavily marketed in black communities and that blacks have disproportionately higher rates of death and disease related to smoking, according to the Times. According to the Times, some smokers "refuse such wholesale interference with personal choices" and others "believe that having their menthol cigarettes snatched away may be just what they motive to oddment their habit."
The Times notes that it "may take more than a ban -- or the health warnings or the $5 pack -- to stop some smokers." Justine Love -- a 54-year-old black Washington, D.C., wireless personality wHO smoked menthol cigarettes for 30 geezerhood and now gives testimonials and public service announcements on her radio station -- said, "This is a very personal decision, and you don't need anybody to tell you what you can or can't do." She adds, "I don't say, 'You should halt smoking.' I give encouragement to quit. I tell them I saved $139 in the get-go month" (New York Times, 8/3).
Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for electronic mail delivery at http://www.kaisernetwork.
The New York Times on Sunday examined how smokers ar left in the middle of "this maelstrom of debate" on whether menthol-flavored cigarettes should be included in the legislation that would allow FDA to ban flavored additives (Navarro, New York Times, 8/3).
The House last week by a veto-proof 326-102 vote approved lawmaking (HR 1108) that would give FDA the confidence to determine tobacco products. The metre, introduced by Rep. Henry Waxman (D-Calif.), would allow FDA to ban flavored additives, with an exemption for menthol flavoring. Some black anti-smoking advocates criticized the exemption, noting that many black smokers use mentholated cigarettes. The National African American Tobacco Prevention Network withdrew its support for the bill because of the menthol exemption. Seventy-five pct of black smokers economic consumption mentholated tobacco products. Menthol brands account for about 28% of the $70 billion U.S. cigarette market.
It is intellection that menthol and other additives mightiness mask the harshness of tobacco, which could cook it easier for teenagers to begin smoking. Researchers also receive questioned whether menthol plays a character in disproportional rates of cancer related to to smoking among blacks. A recent study from Harvard University found that some butt makers by choice "manipulated menthol levels to attract young people" (Kaiser Health Disparities Report, 7/31).
The Times reports that menthol cigarettes have historically been heavily marketed in black communities and that blacks have disproportionately higher rates of death and disease related to smoking, according to the Times. According to the Times, some smokers "refuse such wholesale interference with personal choices" and others "believe that having their menthol cigarettes snatched away may be just what they motive to oddment their habit."
The Times notes that it "may take more than a ban -- or the health warnings or the $5 pack -- to stop some smokers." Justine Love -- a 54-year-old black Washington, D.C., wireless personality wHO smoked menthol cigarettes for 30 geezerhood and now gives testimonials and public service announcements on her radio station -- said, "This is a very personal decision, and you don't need anybody to tell you what you can or can't do." She adds, "I don't say, 'You should halt smoking.' I give encouragement to quit. I tell them I saved $139 in the get-go month" (New York Times, 8/3).
Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for electronic mail delivery at http://www.kaisernetwork.
Thursday 26 June 2008
VH1 and the Broadcast Film Critics Association Set the Date for the 14th Annual 'Critics' Choice Awards'
The First Major Awards Show Of The 2009 Season Will Air Live on VH1 on
Thursday, January 8, 2009 from the Santa Monica Civic Auditorium
NEW YORK, June 23 -- For the second year in a row, VH1
will televise the A-list excitement from the Broadcast Film Critics
Association's (BFCA) "Critics' Choice Awards" gala live from the Santa
Monica Civic Auditorium on Thursday, January 8, 2009. The awards are
bestowed annually by the BFCA to honor the finest in cinematic achievement.
Since its inception in 1995, the "Critics' Choice Awards" has become a
star-studded bellwether event of the movie awards season. The "Critics'
Choice Awards" is the first major award show of the year.
In addition, the BFCA announced today the following timeline regarding
the nomination and balloting process for the 14th annual "Critics' Choice
Awards," recognizing the best among 2008 film releases:
-- December 1, 2008 - Nominating ballots go out to the BFCA members
-- December 7, 2008 - Deadline for returning nominating ballots
-- December 9, 2008 - Critics' Choice Awards nominees announced
-- January 5, 2009 - Final ballots go out to the BFCA members
-- January 7, 2009 - Deadline for casting final ballots
The BFCA consistently picks nominees and winners that go on to garner
more Academy Award nominations and wins than any other of the movie awards
shows. It provides television viewers with their first opportunity to see
all the top awards season contenders in one place.
In 2008 alone, the "Critics' Choice Awards" gave awards to 16 of the 20
Oscar nominees in the acting categories. All five of the Academy Award
nominees for Best Picture were first Critics' Choice Award nominees, and
since 1999 the BFCA has honored 48 of 50 Oscar nominees in the Best Picture
category.
"Despite the challenges presented by the writers strike earlier this
year, the BFCA and Joey Berlin literally moved heaven and earth with us to
produce the first must-attend event of the awards season filled with
Hollywood's A- listers. We can't wait to create an even bigger show this
time around," said Tom Calderone, Executive Vice President and General
Manager, VH1.
"The BFCA was blown away by VH1's steadfast commitment to the Critics'
Choice Awards under such trying circumstances last year - and its
sensational creative team helped us deliver a great show in the middle of a
crippling strike," noted Berlin, BFCA President and Critics' Choice Awards
Executive Producer. "With Bob Bain returning for his fourth year as
Executive Producer and the entire VH1 organization behind us again, this
will surely be our best show ever."
The "Critics' Choice Awards" is always a hot ticket event for
entertainment A-listers. Presenters at the show in 2008 were a who's who of
Hollywood including: George Clooney, Katie Holmes, Marion Cotillard, Snoop
Dogg, Allison Janney, Emile Hirsch, Marcia Gay Harden, Ray Liotta, Steve
Zahn, Kyra Sedgwick, Leslie Mann, Marisa Tomei, Eddie Izzard, Emily
Deschanel, Cuba Gooding Jr., Chris O'Donnell and Feist. Also appearing on
the show: Angelina Jolie for "A Mighty Heart," Brad Pitt, Don Cheadle, Sean
Penn, the cast of "Hairspray" including Queen Latifah, Nikki Blonksy,
Amanda Bynes, Brittany Snow and Elijah Kelly, Adam Shankman, Casey Affleck,
Javier Bardem, the cast of "Juno" including Ellen Page, Allison Janney,
Russ Smith, Lianne Halfon and JK Simmons, AnnaSophia Robb, Leslie Man,
Julian Schnabel for "The Diving Bell and the Butterfly," David Silverman,
Matt Groening, Mike Scully, Eddie Vedder, Brad Bird, Daniel Day-Lewis, Hal
Holbrook, Neal McDonough, Kathleen Robertson, and Joe Wright.
The Broadcast Film Critics Association is the largest film critics'
organization in the United States and Canada, representing more than 200
television, radio and online critics. BFCA members are the primary source
of information for today's film going public. The very first opinion a
moviegoer hears about new releases at the multiplex or the art house
usually comes from one of its members.
Once again, VH1 will expand elements of both shows online at VH1.com
and on VH1 Mobile. Exclusive video footage from the event will include
celebrity interviews, "behind-the-scenes" footage and more. Additional
multiplatform plans will be announced closer to the event.
"The 14th Annual Critics' Choice Awards" will be executive produced by
Bob Bain for Bob Bain Productions and Joey Berlin for Berlin Entertainment.
Lee Rolontz is the executive producer for VH1.
VH1 connects viewers to the music, artists and pop culture that matter
to them most with TV series, specials, live events, exclusive online
content and public affairs initiatives. VH1 is available in 95 million
households in the U.S. VH1 also has an array of digital channels and
services including VH1Classic, VH1 Soul, VH1 Mobile, VH1Games and extensive
broadband video on VH1.com. Connect with VH1 at VH1.com.
PRESS CONTACT:
Scott Acord/VH1 Lori Bogin/VH1
Ph: 310/752-8075 Ph: 212/846-7131
See Also
Thursday, January 8, 2009 from the Santa Monica Civic Auditorium
NEW YORK, June 23 -- For the second year in a row, VH1
will televise the A-list excitement from the Broadcast Film Critics
Association's (BFCA) "Critics' Choice Awards" gala live from the Santa
Monica Civic Auditorium on Thursday, January 8, 2009. The awards are
bestowed annually by the BFCA to honor the finest in cinematic achievement.
Since its inception in 1995, the "Critics' Choice Awards" has become a
star-studded bellwether event of the movie awards season. The "Critics'
Choice Awards" is the first major award show of the year.
In addition, the BFCA announced today the following timeline regarding
the nomination and balloting process for the 14th annual "Critics' Choice
Awards," recognizing the best among 2008 film releases:
-- December 1, 2008 - Nominating ballots go out to the BFCA members
-- December 7, 2008 - Deadline for returning nominating ballots
-- December 9, 2008 - Critics' Choice Awards nominees announced
-- January 5, 2009 - Final ballots go out to the BFCA members
-- January 7, 2009 - Deadline for casting final ballots
The BFCA consistently picks nominees and winners that go on to garner
more Academy Award nominations and wins than any other of the movie awards
shows. It provides television viewers with their first opportunity to see
all the top awards season contenders in one place.
In 2008 alone, the "Critics' Choice Awards" gave awards to 16 of the 20
Oscar nominees in the acting categories. All five of the Academy Award
nominees for Best Picture were first Critics' Choice Award nominees, and
since 1999 the BFCA has honored 48 of 50 Oscar nominees in the Best Picture
category.
"Despite the challenges presented by the writers strike earlier this
year, the BFCA and Joey Berlin literally moved heaven and earth with us to
produce the first must-attend event of the awards season filled with
Hollywood's A- listers. We can't wait to create an even bigger show this
time around," said Tom Calderone, Executive Vice President and General
Manager, VH1.
"The BFCA was blown away by VH1's steadfast commitment to the Critics'
Choice Awards under such trying circumstances last year - and its
sensational creative team helped us deliver a great show in the middle of a
crippling strike," noted Berlin, BFCA President and Critics' Choice Awards
Executive Producer. "With Bob Bain returning for his fourth year as
Executive Producer and the entire VH1 organization behind us again, this
will surely be our best show ever."
The "Critics' Choice Awards" is always a hot ticket event for
entertainment A-listers. Presenters at the show in 2008 were a who's who of
Hollywood including: George Clooney, Katie Holmes, Marion Cotillard, Snoop
Dogg, Allison Janney, Emile Hirsch, Marcia Gay Harden, Ray Liotta, Steve
Zahn, Kyra Sedgwick, Leslie Mann, Marisa Tomei, Eddie Izzard, Emily
Deschanel, Cuba Gooding Jr., Chris O'Donnell and Feist. Also appearing on
the show: Angelina Jolie for "A Mighty Heart," Brad Pitt, Don Cheadle, Sean
Penn, the cast of "Hairspray" including Queen Latifah, Nikki Blonksy,
Amanda Bynes, Brittany Snow and Elijah Kelly, Adam Shankman, Casey Affleck,
Javier Bardem, the cast of "Juno" including Ellen Page, Allison Janney,
Russ Smith, Lianne Halfon and JK Simmons, AnnaSophia Robb, Leslie Man,
Julian Schnabel for "The Diving Bell and the Butterfly," David Silverman,
Matt Groening, Mike Scully, Eddie Vedder, Brad Bird, Daniel Day-Lewis, Hal
Holbrook, Neal McDonough, Kathleen Robertson, and Joe Wright.
The Broadcast Film Critics Association is the largest film critics'
organization in the United States and Canada, representing more than 200
television, radio and online critics. BFCA members are the primary source
of information for today's film going public. The very first opinion a
moviegoer hears about new releases at the multiplex or the art house
usually comes from one of its members.
Once again, VH1 will expand elements of both shows online at VH1.com
and on VH1 Mobile. Exclusive video footage from the event will include
celebrity interviews, "behind-the-scenes" footage and more. Additional
multiplatform plans will be announced closer to the event.
"The 14th Annual Critics' Choice Awards" will be executive produced by
Bob Bain for Bob Bain Productions and Joey Berlin for Berlin Entertainment.
Lee Rolontz is the executive producer for VH1.
VH1 connects viewers to the music, artists and pop culture that matter
to them most with TV series, specials, live events, exclusive online
content and public affairs initiatives. VH1 is available in 95 million
households in the U.S. VH1 also has an array of digital channels and
services including VH1Classic, VH1 Soul, VH1 Mobile, VH1Games and extensive
broadband video on VH1.com. Connect with VH1 at VH1.com.
PRESS CONTACT:
Scott Acord/VH1 Lori Bogin/VH1
Ph: 310/752-8075 Ph: 212/846-7131
See Also
Wednesday 18 June 2008
Joan Rivers - Joan Rivers Apologises After Loose Women Lewdness
Joan Rivers has apologised for swearing live on air on daytime TV show Loose Women.
The comedienne had been discussing Russell Crowe on the ITV1 show when she swore, expecting that her language would be edited out.
But despite the 75-year-old warning: "Get ready to bleep this" before her comment, the producers of the talkshow did not add an editorial bleep over the swear word.
"We do apologise for that," said host Jackie Brambles, after Rivers' remark. "Joan didn't realise that we were absolutely live."
And in a statement issued after the show, the stand-up great admitted: "Yes, I swore, and I'm so f****** sorry.
"No one told me the TV show Loose Women was a reality show and that I would be voted off," she added.
"It's funny: offstage, I hardly ever use profanity. My favourite four-letter word is 'shop.' "
An ITV statement issued after the show said: "Guests are always briefed that it is a live daytime show and are reminded not to swear or use inappropriate language.
"An editorial decision was taken that Joan Rivers should not appear in the final part of the programme," a spokeswoman added.
"We would like to apologise to Loose Women viewers for the inappropriate language used on [the] show."
18/06/2008 08:50:59
See Also
Monday 9 June 2008
Lily Allen is Glamour Woman of the year
Lilly Allen at Glamour magazine's Women Of The Year Awards at Berkeley Square Gardens in London Tuesday, June 3. Photo Credit: Splash News
June 4, 2008 () - Lilly Allen received the Editor's Special Award at Glamour magazine's Women Of The Year Awards at Berkeley Square Gardens in London Tuesday, June 3.
The 23-year-old singer and TV presenter wowed in a pink hair do and a white off shoulder sleeveless ankle length dress.
The awards, referred to as Glammies, recognize women achievers in fields such as music, TV, film and theatre.
Lilly Allen at Glamour magazine's Women Of The Year Awards at Berkeley Square Gardens in London Tuesday, June 3. Photo Credit: Splash News
"With reams of column inches to match her considerable talents, no Women of the Year line-up could be complete without the one and only Lily Allen," said Glamour editor Jo Elvin.
The Spice Girls, who staged a comeback tour, from late 2007 to early 2008, won the best band category.
June 4, 2008 () - Lilly Allen received the Editor's Special Award at Glamour magazine's Women Of The Year Awards at Berkeley Square Gardens in London Tuesday, June 3.
The 23-year-old singer and TV presenter wowed in a pink hair do and a white off shoulder sleeveless ankle length dress.
The awards, referred to as Glammies, recognize women achievers in fields such as music, TV, film and theatre.
Lilly Allen at Glamour magazine's Women Of The Year Awards at Berkeley Square Gardens in London Tuesday, June 3. Photo Credit: Splash News
"With reams of column inches to match her considerable talents, no Women of the Year line-up could be complete without the one and only Lily Allen," said Glamour editor Jo Elvin.
The Spice Girls, who staged a comeback tour, from late 2007 to early 2008, won the best band category.
Monday 2 June 2008
'Guitar Hero' Sequel Takes Aim At 'Rock Band,' Adds Drums And Music Creation -- In Multiplayer
Activision revealed details on the latest installment in their juggernaut franchise, "Guitar Hero: World Tour."
Tuesday 27 May 2008
Judi Dench - Dench To Be Made Doctor With Honorary Degree
Veteran actress DAME JUDI DENCH is to receive an honorary degree from one of the U.K.'s oldest universities.
The James Bond star's achievements on the stage and screen will be recognised by Scotland's University of St Andrews when she is made a Doctor of Letters at the school's summer graduation ceremony in June (08).
And the 73-year-old is delighted by the news.
She says, "I am thrilled to be coming to St Andrews and I am looking forward to it enormously."
See Also
Sunday 18 May 2008
IFI announces its new director
IFI announces its new director
The fresh Director of the Irish people Film Bring has been announced.
Sarah Glennie will exact up the position in autumn 2008.
Glennie has previously worked as Director of the Model Arts and Niland Gallery and Commissioner of the Irish whiskey Pavillion at the Venice Biennale 2005.
She has curated projects for PS1 MoMA, Fresh York, and Bobber 2005 and held positions at the Patrick Henry Thomas Moore Foundation and the Irish Gaelic Museum of Bodoni Art.
Commenting on Glennie's appointee, Eve-Anne Cullinan, Chairman of IFI, said: "Sarah has a riches of have in strategic cultural planning and of run and workings in public cultural institutions both in Emerald Isle and internationally. We are delighted to receive Sarah Glennie to IFI to lead one of the country's most popular cultural venues into an exciting period of time in its history."
Among the new projects to be undertaken by the IFI are a renovation of the IFI center in Dublin's Eustace Street; a collaboration with the Dundalk Institute of Engineering on a freshly adroitness for the Irish Moving picture Archive and a three-year strategy plan.
Thursday 8 May 2008
Britney taking advice from David Hasselhoff?
Britney taking advice from David Hasselhoff?
Britney Spears has reportedly started pickings advice from former 'Baywatch' star David Hasselhoff in a bid to overcome her troubles.
According to a report in the Daily Whizz, Spears' father of the Church Jamie believes that Hasselhoff can buoy provide a positive degree influence for the isaac Bashevis Singer.
The paper is reportage that Spears has been spending meter at Hasselhoff's plate where she has been watching episodes of 'Knight Rider' and partaking in primal wow therapy.
A source said: "Britney turns up looking for like she's carrying a boastfully old bag of badly on her support and the disturbance can catch a bite a good deal, only she always leaves with a smile on her face."
The newspaper too claimed that Lynne Spears, Spears' mother, is angry that her ex is lease the pair off assemble and seemingly thinks it is all a publicity stunt for Jamie's freshly eatery.
A source added: "Britney's mum is incandescent with fury at Jamie's stupidity. She wants her girl to stay out of the headlines, only she thinks her ex-husband just wants promotion for his freshly business."
Saturday 26 April 2008
IFI announces its new director
IFI announces its new director
The freshly Film director of the Irish Film Constitute has been announced.
Sarah Glennie will take up the place in fall 2008.
Glennie has antecedently worked as Director of the Model Humanistic discipline and Niland Gallery and Commissioner of the Irish Pavillion at the Venezia Biennale 2005.
She has curated projects for PS1 MoMA, Fresh York, and Bottle cork 2005 and held positions at the Henry Moore Foundation and the Irish whisky Museum of Modern Artistic production.
Commenting on Glennie's date, Eve-Anne Cullinan, Chairman of IFI, said: "Sarah has a wealth of go through in strategic cultural provision and of run and working in public cultural institutions both in Republic of Ireland and internationally. We ar delighted to welcome Sarah Glennie to IFI to lead ace of the country's most popular cultural venues into an exciting period in its chronicle."
Among the new projects to be undertaken by the IFI are a refurbishment of the IFI centre in Dublin's Eustace Street; a collaborationism with the Dundalk Found of Engineering science on a fresh facility for the Irish Film Archive and a three-year strategy design.
Thursday 24 April 2008
The DAMNED
Artist: The DAMNED
Genre(s):
Rock: Punk-Rock
Hardcore
Discography:
Not Of This Earth
Year: 1996
Tracks: 12
Fiendish Shadows (Live)
Year: 1996
Tracks: 15
Live at Newcastle
Year: 1994
Tracks: 10
Phantasmagoria
Year: 1985
Tracks: 11
Damned Damned Damned
Year: 1977
Tracks: 12
The Black Album
Year:
Tracks: 12
Music For Pleasure
Year:
Tracks: 14
Machine Gun Etiquette
Year:
Tracks: 16
Fans beg Winehouse to quit drugs after video
Fans beg Winehouse to quit drugs after video
Fans of troubled singer Amy Winehouse have begged her to get help after she was caught on video apparently smoking crack cocaine.
Footage obtained by The Sun appears to show her inhaling fumes from a crack pipe after an apparent 19-minute drugs binge in which she snorted ecstasy, cocaine and admitted to taking Valium tablets.
The disturbing images were said to have been filmed during a party at Winehouse's London home in the early hours of last Friday, just before she attended a court hearing for husband Blake Fielder-Civil. He is awaiting trial on charges of assault and conspiracy to pervert the course of justice.
Looking dishevelled and wearing a grubby black vest in the video, Winehouse was barely able to talk. When friends ask her to go out with them, she is heard to reply: "I'd be useless to you because I've had about six Valium."
On the singer's website, fans warned the 24-year-old that she would die unless she sought help.
One fan said: "That video of you at home, which is now doing the rounds, will hopefully be instrumental in getting you where you need to be."
The fan quoted the mother of the late Nirvana front man Kurt Cobain, warning Winehouse not to "join that stupid club" of dead rock stars.
Saturday 19 April 2008
Christopher Franke and The Berl
Artist: Christopher Franke and The Berl
Genre(s):
Other
Discography:
New Music For Films, Vol. 2
Year: 2000
Tracks: 16
Subscribe to:
Posts (Atom)